Emerald Mutual Fund Advisers Trust Raises Stake in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Emerald Mutual Fund Advisers Trust boosted its stake in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 94.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 841,643 shares of the medical technology company's stock after buying an additional 408,516 shares during the period. Emerald Mutual Fund Advisers Trust owned approximately 0.59% of Alphatec worth $7,726,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of ATEC. Barclays PLC lifted its holdings in shares of Alphatec by 362.3% in the 3rd quarter. Barclays PLC now owns 170,546 shares of the medical technology company's stock worth $948,000 after acquiring an additional 133,653 shares during the last quarter. Invst LLC lifted its stake in Alphatec by 3.7% during the third quarter. Invst LLC now owns 158,549 shares of the medical technology company's stock worth $882,000 after purchasing an additional 5,630 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Alphatec by 299.3% during the third quarter. Franklin Resources Inc. now owns 64,450 shares of the medical technology company's stock worth $343,000 after buying an additional 48,308 shares during the period. Courier Capital LLC grew its stake in shares of Alphatec by 76.9% in the fourth quarter. Courier Capital LLC now owns 69,000 shares of the medical technology company's stock valued at $633,000 after buying an additional 30,000 shares in the last quarter. Finally, Ballentine Partners LLC purchased a new stake in shares of Alphatec in the 4th quarter valued at $120,000. Institutional investors and hedge funds own 66.35% of the company's stock.

Alphatec Stock Up 8.5 %

Shares of Alphatec stock traded up $0.94 during trading on Friday, hitting $12.00. 4,701,141 shares of the stock were exchanged, compared to its average volume of 2,070,936. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The firm's 50-day moving average price is $10.46 and its 200 day moving average price is $9.86. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of -9.38 and a beta of 1.20. Alphatec Holdings, Inc. has a 12-month low of $4.88 and a 12-month high of $13.79.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.23). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The business had revenue of $169.18 million for the quarter, compared to analysts' expectations of $167.57 million. During the same period last year, the firm earned ($0.34) earnings per share. The firm's quarterly revenue was up 22.2% on a year-over-year basis. As a group, analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Patrick Miles sold 43,459 shares of Alphatec stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $11.95, for a total transaction of $519,335.05. Following the sale, the chief executive officer now directly owns 6,065,772 shares in the company, valued at $72,485,975.40. This trade represents a 0.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP David Sponsel sold 36,256 shares of the company's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $11.42, for a total transaction of $414,043.52. Following the completion of the transaction, the executive vice president now owns 735,074 shares of the company's stock, valued at $8,394,545.08. This represents a 4.70 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 222,113 shares of company stock valued at $2,519,725. 22.80% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on ATEC shares. StockNews.com raised Alphatec from a "sell" rating to a "hold" rating in a research report on Friday, February 28th. HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a report on Monday, April 14th. Piper Sandler reiterated an "overweight" rating and set a $15.00 target price (up from $13.00) on shares of Alphatec in a report on Friday. Barclays raised their price target on shares of Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Wednesday, January 22nd. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $16.00 price objective on shares of Alphatec in a research report on Friday. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $17.89.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.